Page last updated: 2024-10-25

citalopram and Anhedonia

citalopram has been researched along with Anhedonia in 12 studies

Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.

Anhedonia: Inability to experience pleasure due to impairment or dysfunction of normal psychological and neurobiological mechanisms. It is a symptom of many PSYCHOTIC DISORDERS (e.g., DEPRESSIVE DISORDER, MAJOR; and SCHIZOPHRENIA).

Research Excerpts

ExcerptRelevanceReference
" Eighty-seven participants in the first Canadian Biomarker Integration Network in Depression (CAN-BIND-1) protocol received 8 weeks of open-label escitalopram."7.96Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. ( Arnott, SR; Ceniti, AK; Davis, AD; Downar, J; Dunlop, K; Foster, JA; Frey, BN; Harris, JK; Hassel, S; Kennedy, SH; Lam, RW; MacQueen, GM; Mansouri, F; Milev, R; Parikh, SV; Rizvi, SJ; Rotzinger, S; Schulze, L; Soares, CN; Strother, SC; Turecki, G; Uher, R; Zamyadi, M, 2020)
" The aim of the present study was to investigate whether stress-induced anhedonia could be prevented by treatments with escitalopram or novel herbal treatment (NHT) in an animal model of depression."7.85Escitalopram and NHT normalized stress-induced anhedonia and molecular neuroadaptations in a mouse model of depression. ( Barak, S; Burstein, O; Chen, G; Doron, R; Franko, M; Gale, E; Handelsman, A; Hirshler, Y; Motsan, S; Shamir, A; Simhon, O; Toledano, R, 2017)
" Alleviation of anhedonia was assessed in chronic mild stress model using sucrose preference test."4.12Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization. ( Abraham, R; Gagginapally, SR; Goura, V; Goyal, VK; Jasti, V; Jayarajan, P; Kallepalli, R; Medapati, RB; Mohammed, AR; Nirogi, R; Palacharla, VRC; Pandey, SK; Petlu, S; Subramanian, R; Tadiparthi, J; Thentu, JB, 2022)
" Eighty-seven participants in the first Canadian Biomarker Integration Network in Depression (CAN-BIND-1) protocol received 8 weeks of open-label escitalopram."3.96Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. ( Arnott, SR; Ceniti, AK; Davis, AD; Downar, J; Dunlop, K; Foster, JA; Frey, BN; Harris, JK; Hassel, S; Kennedy, SH; Lam, RW; MacQueen, GM; Mansouri, F; Milev, R; Parikh, SV; Rizvi, SJ; Rotzinger, S; Schulze, L; Soares, CN; Strother, SC; Turecki, G; Uher, R; Zamyadi, M, 2020)
" Change in reward sensitivity during the first 2 weeks of treatment was associated with improved depressive symptoms and anhedonia following 8 weeks of treatment with escitalopram."3.91Early change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: a CAN-BIND-1 report. ( Allen, TA; Frey, BN; Kennedy, SH; Lam, RW; MacQueen, GM; Milev, R; Müller, DJ; Quilty, LC; Rizvi, SJ; Uher, R, 2019)
" The aim of the present study was to investigate whether stress-induced anhedonia could be prevented by treatments with escitalopram or novel herbal treatment (NHT) in an animal model of depression."3.85Escitalopram and NHT normalized stress-induced anhedonia and molecular neuroadaptations in a mouse model of depression. ( Barak, S; Burstein, O; Chen, G; Doron, R; Franko, M; Gale, E; Handelsman, A; Hirshler, Y; Motsan, S; Shamir, A; Simhon, O; Toledano, R, 2017)
"Late-life depression is associated with substantial heterogeneity in clinical presentation, disability, and response to antidepressant treatment."1.91Cognitive, Disability, and Treatment Outcome Implications of Symptom-Based Phenotyping in Late-Life Depression. ( Conway, C; Elson, D; Kang, H; Sudol, K; Szymkowicz, SM; Taylor, WD, 2023)
"Anhedonia is a core symptom of major depressive disorder (MDD)."1.46Patients with major depressive disorder exhibit reduced reward size coding in the striatum. ( Akiyama, Y; Awai, K; Fujii, Y; Ichikawa, N; Kaichi, Y; Minagawa, H; Mori, A; Okada, G; Okamoto, Y; Takaishi, Y; Takamura, M; Toki, S; Yamamoto, T; Yamawaki, S, 2017)
" We compared different phenotypes from the chronic mild stress (CMS) model of depression using chronic administration with two selective serotonin reuptake inhibitors (SSRIs), escitalopram and sertraline."1.38Vesicular signalling and immune modulation as hedonic fingerprints: proteomic profiling in the chronic mild stress depression model. ( Bak, S; Bisgaard, CF; Christensen, T; Enghild, JJ; Jensen, ON; Wiborg, O, 2012)
" Depression-related transcriptomic changes in gene expression profiles were investigated in laser-captured microdissected (LCM) rat hippocampal granular cell layers (GCL) using the chronic mild stress (CMS) rat model of depression and chronic administration of two selective serotonin reuptake inhibitors (SSRIs), escitalopram and sertraline."1.37Biomarkers of anhedonic-like behavior, antidepressant drug refraction, and stress resilience in a rat model of depression. ( Bisgaard, CF; Christensen, T; Wiborg, O, 2011)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's8 (66.67)24.3611
2020's4 (33.33)2.80

Authors

AuthorsStudies
Strekalova, T1
Pavlov, D1
Trofimov, A1
Anthony, DC1
Svistunov, A1
Proshin, A1
Umriukhin, A1
Lyundup, A1
Lesch, KP1
Cespuglio, R1
Nirogi, R1
Abraham, R1
Jayarajan, P1
Goura, V1
Kallepalli, R1
Medapati, RB1
Tadiparthi, J1
Goyal, VK1
Pandey, SK1
Subramanian, R1
Petlu, S1
Thentu, JB1
Palacharla, VRC1
Gagginapally, SR1
Mohammed, AR1
Jasti, V1
Sudol, K1
Conway, C1
Szymkowicz, SM1
Elson, D1
Kang, H1
Taylor, WD1
Dunlop, K1
Rizvi, SJ2
Kennedy, SH2
Hassel, S1
Strother, SC1
Harris, JK1
Zamyadi, M1
Arnott, SR1
Davis, AD1
Mansouri, F1
Schulze, L1
Ceniti, AK1
Lam, RW2
Milev, R2
Rotzinger, S1
Foster, JA1
Frey, BN2
Parikh, SV1
Soares, CN1
Uher, R2
Turecki, G1
MacQueen, GM2
Downar, J1
Takamura, M1
Okamoto, Y1
Okada, G1
Toki, S1
Yamamoto, T1
Ichikawa, N1
Mori, A1
Minagawa, H1
Takaishi, Y1
Fujii, Y1
Kaichi, Y1
Akiyama, Y1
Awai, K1
Yamawaki, S1
Burstein, O1
Franko, M1
Gale, E1
Handelsman, A1
Barak, S1
Motsan, S1
Shamir, A1
Toledano, R1
Simhon, O1
Hirshler, Y1
Chen, G1
Doron, R1
Allen, TA1
Müller, DJ1
Quilty, LC1
Alexander, L1
Gaskin, PLR1
Sawiak, SJ1
Fryer, TD1
Hong, YT1
Cockcroft, GJ1
Clarke, HF1
Roberts, AC1
Levada, OA1
Troyan, AS1
Christensen, T2
Bisgaard, CF2
Wiborg, O2
Liu, R1
Dang, W1
Jianting, M1
Su, C1
Wang, H1
Chen, Y1
Tan, Q1
Bak, S1
Jensen, ON1
Enghild, JJ1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)[NCT05017311]Phase 4400 participants (Anticipated)Interventional2023-01-20Recruiting
Integrated Biological Markers for the Prediction of Treatment Response in Depression[NCT01655706]Phase 3211 participants (Actual)Interventional2012-04-23Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for citalopram and Anhedonia

ArticleYear
Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram.
    Journal of affective disorders, 2019, 05-01, Volume: 250

    Topics: Adult; Anhedonia; Antidepressive Agents; Citalopram; Cognition; Cognitive Dysfunction; Depressive Di

2019

Other Studies

11 other studies available for citalopram and Anhedonia

ArticleYear
Hippocampal Over-Expression of Cyclooxygenase-2 (COX-2) Is Associated with Susceptibility to Stress-Induced Anhedonia in Mice.
    International journal of molecular sciences, 2022, Feb-13, Volume: 23, Issue:4

    Topics: Anhedonia; Animals; Antidepressive Agents; Celecoxib; Citalopram; Cyclooxygenase 2; Depression; Hind

2022
Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization.
    Psychopharmacology, 2022, Volume: 239, Issue:7

    Topics: Anhedonia; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Citalopram; Depressive

2022
Cognitive, Disability, and Treatment Outcome Implications of Symptom-Based Phenotyping in Late-Life Depression.
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2023, Volume: 31, Issue:11

    Topics: Aged; Anhedonia; Citalopram; Cognition; Depression; Escitalopram; Fatigue; Humans; Sleep Initiation

2023
Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2020, Volume: 45, Issue:8

    Topics: Anhedonia; Biomarkers; Canada; Citalopram; Depression; Depressive Disorder, Major; Humans; Magnetic

2020
Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2020, Volume: 45, Issue:8

    Topics: Anhedonia; Biomarkers; Canada; Citalopram; Depression; Depressive Disorder, Major; Humans; Magnetic

2020
Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2020, Volume: 45, Issue:8

    Topics: Anhedonia; Biomarkers; Canada; Citalopram; Depression; Depressive Disorder, Major; Humans; Magnetic

2020
Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2020, Volume: 45, Issue:8

    Topics: Anhedonia; Biomarkers; Canada; Citalopram; Depression; Depressive Disorder, Major; Humans; Magnetic

2020
Patients with major depressive disorder exhibit reduced reward size coding in the striatum.
    Progress in neuro-psychopharmacology & biological psychiatry, 2017, 10-03, Volume: 79, Issue:Pt B

    Topics: Adult; Anhedonia; Anticipation, Psychological; Antidepressive Agents, Second-Generation; Brain Mappi

2017
Escitalopram and NHT normalized stress-induced anhedonia and molecular neuroadaptations in a mouse model of depression.
    PloS one, 2017, Volume: 12, Issue:11

    Topics: Anhedonia; Animals; Antidepressive Agents, Second-Generation; Brain-Derived Neurotrophic Factor; Cit

2017
Early change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: a CAN-BIND-1 report.
    Psychological medicine, 2019, Volume: 49, Issue:10

    Topics: Adolescent; Adult; Anhedonia; Antidepressive Agents; Aripiprazole; Citalopram; Depressive Disorder,

2019
Fractionating Blunted Reward Processing Characteristic of Anhedonia by Over-Activating Primate Subgenual Anterior Cingulate Cortex.
    Neuron, 2019, 01-16, Volume: 101, Issue:2

    Topics: Anhedonia; Animals; Blood Pressure; Callithrix; Citalopram; Conditioning, Classical; Discrimination,

2019
Biomarkers of anhedonic-like behavior, antidepressant drug refraction, and stress resilience in a rat model of depression.
    Neuroscience, 2011, Nov-24, Volume: 196

    Topics: Anhedonia; Animals; Biomarkers; Citalopram; Depression; Disease Models, Animal; Drug Resistance; Eat

2011
Citalopram alleviates chronic stress induced depression-like behaviors in rats by activating GSK3β signaling in dorsal hippocampus.
    Brain research, 2012, Jul-27, Volume: 1467

    Topics: Anhedonia; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; beta Catenin; Blottin

2012
Vesicular signalling and immune modulation as hedonic fingerprints: proteomic profiling in the chronic mild stress depression model.
    Journal of psychopharmacology (Oxford, England), 2012, Volume: 26, Issue:12

    Topics: Anhedonia; Animals; Citalopram; Depression; Disease Models, Animal; Hippocampus; Immune System; Lase

2012